The global Drug Eluting Stent Market is witnessing significant expansion due to the increasing burden of cardiovascular diseases (CVDs), growing adoption of minimally invasive cardiac procedures, and continuous advancements in stent technologies. The market was estimated at USD 4.0 billion in 2025 and is projected to reach USD 6.7 billion by 2033, growing at a CAGR of 6.7% from 2026 to 2033.

Drug eluting stents (DES) have transformed interventional cardiology by reducing restenosis rates and improving long-term patient outcomes compared to bare-metal stents. As healthcare systems worldwide continue prioritizing early cardiac intervention and precision-based treatment, the demand for advanced DES technologies is expected to accelerate substantially over the coming years.

Rising Prevalence of Cardiovascular Diseases and Associated Risk Factors

The growing prevalence of cardiovascular diseases remains the primary growth driver for the Drug Eluting Stent Market. Coronary artery disease, heart failure, and peripheral artery disease are increasing globally due to several lifestyle-related and demographic factors, including:

• Obesity
• Diabetes
• Hypertension
• Sedentary lifestyles
• Aging populations
• Unhealthy dietary habits

As the incidence of these chronic conditions rises, hospitals and cardiac centers are experiencing higher demand for angioplasty, catheter-based interventions, and stenting procedures.

In October 2024, the CDC reported 919,032 deaths in the U.S. from cardiovascular disease in 2023, with coronary heart disease accounting for 371,506 deaths. Approximately 805,000 heart attacks occurred nationwide, including 605,000 first-time heart attacks. Notably, about 1 in 6 CVD-related deaths occurred in adults under 65, highlighting the expanding patient pool requiring interventional treatment.

Download a free sample copy of the Drug Eluting Stent Market report to understand detailed coverage and inclusions in the final report

Another major contributor is the growing obesity epidemic. In December 2025, the CDC released 2024 adult obesity prevalence data across U.S. states and territories. Obesity rates ranged from 25% to over 40%, significantly increasing the risk of chronic conditions such as heart disease and diabetes. This trend is expected to sustain long-term demand for advanced coronary intervention devices, including drug eluting stents.

Increasing Volume of Percutaneous Coronary Intervention (PCI) Procedures

The rising number of Percutaneous Coronary Intervention (PCI) procedures is further strengthening market growth. PCI procedures are widely used to restore blood flow in blocked or narrowed coronary arteries and are considered a standard treatment for coronary artery disease and acute coronary syndromes.

The increasing prevalence of cardiovascular disorders, combined with higher awareness regarding minimally invasive procedures, is fueling PCI adoption globally. Patients increasingly prefer shorter hospital stays, lower procedural risks, and faster recovery times associated with catheter-based interventions.

In May 2025, findings presented at the SCAI Scientific Sessions analyzed 408,060 outpatient PCI procedures conducted between 2020 and 2022. The report showed:

• 1.8% of procedures were performed in ambulatory surgery centers (ASCs)
• 98.2% were conducted in hospital outpatient departments
• PCI utilization in ASCs increased to 0.87 per 10,000 person years
• 30-day adverse events, including mortality, stroke, and bleeding, remained below 2%

These findings indicate a growing shift toward outpatient cardiac procedures, creating new opportunities for drug eluting stent manufacturers to expand product accessibility and procedural efficiency.

Latest Trends Transforming the Drug Eluting Stent Market

Shift Toward Biodegradable Polymer Stents

One of the most important emerging trends is the increasing development of biodegradable polymer-coated stents. These next-generation stents are designed to reduce long-term inflammation and improve vascular healing after implantation. Manufacturers are investing heavily in bioresorbable technologies to enhance patient safety and procedural outcomes.

Growing Focus on Personalized Cardiac Care

Artificial intelligence, imaging-guided interventions, and precision medicine are influencing the future of interventional cardiology. Healthcare providers are increasingly adopting patient-specific treatment approaches that improve stent selection accuracy and procedural success rates.

Expansion of Ambulatory Surgery Centers

The rapid growth of outpatient cardiac care and ambulatory surgery centers is reshaping the competitive landscape. Faster turnaround times, reduced hospitalization costs, and advancements in minimally invasive technologies are supporting this transition.

Technological Advancements in Stent Design

Manufacturers are continuously improving stent flexibility, thinner strut platforms, drug-delivery mechanisms, and polymer technologies to minimize thrombosis risk and enhance long-term efficacy. The integration of advanced materials and coating technologies remains a key competitive differentiator.

Looking for more specific insights? Customize this report to suite your business needs

Key Market Trends & Insights

• The North America drug eluting stents market dominated the global market in 2025 with a revenue share of 44.1%.
• The U.S. drug eluting stents market accounted for the largest share in North America in 2025.
• Based on the type of coating, the polymer-based coating segment held the largest share in 2025.
• Based on end use, the hospitals segment held the largest share in 2025.

Market Size & Forecast

• 2025 Market Size: USD 4.0 Billion
• 2033 Projected Market Size: USD 6.7 Billion
• CAGR (2026-2033): 6.7%
• North America: Largest market in 2025
• Asia Pacific: Fastest growing market

Regional Outlook

North America Leads the Global Market

North America continues to dominate due to:

• Advanced healthcare infrastructure
• High PCI procedure volumes
• Strong reimbursement systems
• Presence of major market players
• Rising awareness regarding early cardiovascular intervention

Asia Pacific Emerging as the Fastest Growing Region

Asia Pacific is projected to witness the fastest growth owing to:

• Rapidly aging populations
• Increasing prevalence of diabetes and hypertension
• Expanding healthcare investments
• Growing access to minimally invasive cardiac procedures
• Rising medical tourism in countries such as India and Southeast Asia

Explore Grand View Horizon to see global and regional level statistics related to the Drug Eluting Stent Market

Key Drug Eluting Stent Company Insights

Leading companies operating in the Drug Eluting Stent Market are focusing on strategic initiatives such as:

• Mergers and acquisitions
• Product innovation
• Geographic expansion
• Distribution partnerships
• Technological collaborations

The competitive landscape remains highly innovation-driven, with companies investing in next-generation stent platforms and advanced coating technologies to strengthen their global market presence.

Key Drug Eluting Stent Companies

The following key companies have been profiled for this study on the drug eluting stent market:

• Boston Scientific Corporation
• Medtronic
• Abbott
• Teleflex Incorporated (BIOTRONIK)
• Terumo Corporation
• B. Braun SE
• Translumina
• MicroPort Scientific Corporation
• Biosensors International Group, Ltd
• Lepu Medical
• iVascular S.L.U.
• SMT
• Meril Life Sciences Pvt. Ltd.
• Concept Medical
• Cardionovum GmbH

Conclusion

The global Drug Eluting Stent Market is entering a transformative growth phase driven by the rising burden of cardiovascular diseases, increasing PCI procedure volumes, and rapid technological advancements in stent development. With healthcare systems emphasizing minimally invasive interventions and precision-based cardiac care, drug eluting stents are expected to remain a cornerstone of coronary artery disease treatment.

Emerging trends such as biodegradable polymers, AI-guided interventions, outpatient cardiac care expansion, and next-generation coating technologies are reshaping market dynamics and opening new growth opportunities for manufacturers worldwide. While North America continues to dominate the industry, Asia Pacific is rapidly emerging as a high-growth region fueled by healthcare modernization and increasing cardiovascular disease prevalence.

As competition intensifies, companies that prioritize innovation, clinical performance, and patient-centric solutions will likely gain a stronger competitive advantage in the evolving global Drug Eluting Stent Market.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…